Johnson & Johnson initiated an application seeking Food and Drug Administration approval of its TAR-200 drug-device combination for the treatment of certain patients with bladder cancer.

TAR-200 is an investigational intravesical drug releasing system designed to provide sustained local delivery of gemcitabine into the bladder. It is placed into the bladder by a healthcare ...

If approved, TAR-200 will be the first intravesical drug-releasing ... method developed by J&J for a sustained delivery of chemotherapy drug gemcitabine directly into the bladder.

TAR-200 is an investigational intravesical drug releasing system designed to provide sustained local delivery of gemcitabine into the bladder. It is placed into the bladder by a healthcare ...

Niktimvo marks the first FDA-approved therapy targeting CSF-1R to address inflammation and fibrosis in chronic graft-versus-host disease. The FDA has approved Incyte’s and Syndax’s Niktimvo ...

TAR-200, an investigational intravesical drug releasing system, is designed to deliver gemcitabine locally to the bladder, offering a potentially less invasive treatment than the current standard, ...

J&J's TAR-200 is an intravesical drug-releasing system that is placed in the bladder to provide sustained local delivery of the chemotherapy drug gemcitabine. TAR-200 is part of the Taris platform ...

Businesses can now self-serve to experience enhanced delivery ef?ciency with ?eet planning, scheduling, and routing technology. BLOOMINGTON, MINNESOTA / ACCESSWIRE / January 15, 2025 / Dispatch ...

TAR-200 is an intravesical drug releasing system that provides sustained local delivery of the chemotherapy drug gemcitabine into the bladder. The system is inserted into the bladder using a co ...